EBS Q2 2023 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$338M+40.9% YoY

Gross Profit

$123M36.5% margin

Operating Income

-$293M-86.7% margin

Net Income

-$261M-77.4% margin

EPS (Diluted)

$-5.15

QoQ Revenue Growth

+105.7%

Cash Flow

Operating Cash Flow

-$114M

Free Cash Flow

-$127M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$1.2B

Stockholders' Equity

$956M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$338M	$240M	+40.9%
Gross Profit	$123M	$19M	+549.5%
Operating Income	-$293M	-$76M	-286.4%
Net Income	-$261M	-$54M	-385.9%

Revenue Segments

Product

$302M89%

Contract Development And Manufacturing

$29M9%

Contracts and Grants

$7M2%

Geographic Segments

Services Segment

$29M100%